[COVID-19: The Perspective Of Nephrology]

Dtsch Med Wochenschr. 2020 Jul;145(15):1068-1073. doi: 10.1055/a-1164-4231. Epub 2020 Jul 30.
[Article in German]

Abstract

Increasing insight into the clinical phenotype and mechanisms of SARS-CoV-2 infections and COVID-19 has identified damage of the kidneys as a key player in the course of the disease. This manuscript summarizes the current knowledge on direct viral infection of kidney tissue, proteinuria and acute kidney injury in COVID-19, and management of patients on chronic dialysis as well as after kidney transplantation. Direct infection of podocytes and proximal tubular cells by SARS-CoV-2 has been confirmed and results in proteinuria and hematuria at an early stage of COVID-19. In this context, any kidney affection is a predictor of worse outcomes among COVID-19 patients irrespective of the initial presentation and increases the risk of acute kidney injury. Specific therapies for kidney damage and acute kidney injury within COVID-19 that could be generally recommended are currently lacking. Patients on chronic hemodialysis in particular are at risk for contracting SARS-CoV-2 infections as indicated by outbreaks and super-spreading events in hemodialysis facilities. Immunosuppressive therapy after kidney transplantation needs to be adapted upon diagnosis of COVID-19 depending on the severity of the initial presentation.

MeSH terms

  • Acute Kidney Injury* / physiopathology
  • Acute Kidney Injury* / virology
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / physiopathology
  • Hematuria
  • Humans
  • Kidney / physiopathology
  • Kidney / virology
  • Pandemics*
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / physiopathology
  • Proteinuria
  • Renal Dialysis
  • Renal Insufficiency, Chronic / therapy
  • Risk Factors
  • SARS-CoV-2